Antibody-dependent cell cytotoxicity to breast cancer targets despite inhibitory KIR signaling.

BACKGROUND Natural killer (NK) cells express killer immunoglobulin-like (KIR) inhibitory receptors, which recognize certain HLA class I molecules (KIR ligands), and stimulatory receptors such as FcgammaRIII. The purpose of this study was to test the possible influence of inhibitory KIR signaling on antibody-dependent cell cytotoxicity (ADCC) mediated by allogeneic NK cells against breast cancer targets. MATERIALS AND METHODS The cytotoxic activity of volunteer donor NK cells against the cell lines SKBR-3, T47D and MCF-7, which have high, low and no HER2 gene amplification, respectively, were studied. Both cell lines and donors were assigned to the C1 or C2 superfamily, defined by the structure of the HLA-Cw molecule. RESULTS It was found that ADCC mediated by allogeneic NK cells occurred despite combinations of NK cells and breast cancer targets predicted to trigger inhibitory KIR signaling. CONCLUSION We suggest that adoptive immunotherapy with allogeneic NK cells and trastuzumab may be an effective combination against breast cancer targets.

[1]  C. Le,et al.  Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. , 2005, Blood.

[2]  R. Handgretinger,et al.  Phenotype and function of human natural killer cells purified by using a clinical-scale immunomagnetic method , 2005, Cancer Immunology, Immunotherapy.

[3]  H. Kirchner,et al.  Kinetics and organ distribution of allogeneic natural killer lymphocytes transfused into patients suffering from renal cell carcinoma. , 2004, Stem cells and development.

[4]  R. Srinivasan,et al.  Allogeneic stem cell transplantation as immunotherapy for nonhematological cancers. , 2004, Seminars in oncology.

[5]  Franco Locatelli,et al.  Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. , 2003, Blood.

[6]  O. Finn,et al.  Cancer vaccines: between the idea and the reality , 2003, Nature Reviews Immunology.

[7]  M. Ernstoff,et al.  Modulation of antitumor immune responses by hematopoietic cytokines , 2003, Cancer.

[8]  H. Fujii,et al.  Impaired antibody-dependent cellular cytotoxicity mediated by herceptin in patients with gastric cancer. , 2002, Cancer research.

[9]  Katia Perruccio,et al.  Effectiveness of Donor Natural Killer Cell Alloreactivity in Mismatched Hematopoietic Transplants , 2002, Science.

[10]  A. Nagler,et al.  Treatment of Leukemia by Alloreactive Lymphocytes and Nonmyeloablative Stem Cell Transplantation , 2002, Journal of Clinical Immunology.

[11]  L. Luznik,et al.  Donor lymphocyte infusions to treat hematologic malignancies in relapse after allogeneic blood or marrow transplantation. , 2002, Cancer control : journal of the Moffitt Cancer Center.

[12]  K. Jiang,et al.  A View to a Kill : Signals Triggering Cytotoxicity 1 , 2002 .

[13]  T. Klingebiel,et al.  Clinical scale isolation of T cell-depleted CD56+ donor lymphocytes in children , 2002, Bone Marrow Transplantation.

[14]  Lyndsay N Harris,et al.  Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  T. Braun,et al.  Prospective trial of chemotherapy and donor leukocyte infusions for relapse of advanced myeloid malignancies after allogeneic stem-cell transplantation. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  R. Wilkinson,et al.  Antibody-dependent cell-mediated cytotoxicity: a flow cytometry-based assay using fluorophores. , 2001, Journal of immunological methods.

[17]  E. Lyon,et al.  Quantification of HER2/neu gene amplification by competitive pcr using fluorescent melting curve analysis. , 2001, Clinical chemistry.

[18]  W. Linehan,et al.  Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. , 2000, The New England journal of medicine.

[19]  H. Kirchner,et al.  Feasibility of the Adoptive Transfusion of Allogenic Human Leukocyte Antigen-Matched Natural Killer Cells in Patients With Renal Cell Carcinoma , 2000, Journal of immunotherapy.

[20]  L. Presta,et al.  Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets , 2000, Nature Medicine.

[21]  Jeffrey S. Miller,et al.  Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody-dependent cellular cytotoxicity against LFA-3 and HER2/neu. , 1999, Experimental hematology.

[22]  G. Bein,et al.  DNA typing for natural killer cell inhibiting HLA-Cw groups NK1 and NK2 by PCR-SSP. , 1998, Journal of immunological methods.

[23]  W Godolphin,et al.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.

[24]  V. Cerundolo,et al.  Dendritic cells: a journey from laboratory to clinic , 2004, Nature Immunology.

[25]  B. Jasani,et al.  A formalin-fixed, paraffin-processed cell line standard for quality control of immunohistochemical assay of HER-2/neu expression in breast cancer. , 2002, American journal of clinical pathology.